Arbutus Biopharma Corporation, a Pennsylvania-based biopharmaceutical firm, announced its dedication to developing innovative therapeutics for chronic Hepatitis B virus infection, SARS-CoV-2, and other coronaviruses. Arbutus' HBV product pipeline comprises AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that inhibits all HBV antigens, including HBsAg expression. The company's research and development programs entail AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor designed to awaken patients' HBV-specific immune system; and small molecule antiviral drugs to help treat coronaviruses, including COVID-19. Arbutus Biopharma Corporation has secured licensing agreements with top firms such as Alnylam Pharmaceuticals, Gritstone Oncology, Qilu Pharmaceuticals, Acuitas Therapeutics, Assembly Biosciences, and Antios Therapeutics. The firm has also clinched a clinical collaboration pact with Vaccitech plc to investigate AB-729. Previously known as Tekmira Pharmaceuticals Corporation, Arbutus Biopharma Corporation was renamed in July 2015.
Arbutus Biopharma's ticker is ABUS
The company's shares trade on the NASDAQ stock exchange
They are based in Warminster, Pennsylvania
There are 51-200 employees working at Arbutus Biopharma
It is arbutusbio.com
Arbutus Biopharma is in the Healthcare sector
Arbutus Biopharma is in the Biotechnology industry
The following five companies are Arbutus Biopharma's industry peers: